Viropro, which has signed a non-binding Letter of Intent for the acquisition of NovaRx, a San Diego based pioneer in immuno-oncology, has announced Dr. Ivor Royston has agreed to join its Board of Directors.
Dr. Royston is Founding Managing Member of Forward Ventures and a recognized leader in cancer research. He is widely recognized as a founding father of San Diego’s biotech industry. In 1978, he co-founded Hybritech, Inc., San Diego’s first biotechnology company, which was subsequently acquired by Eli Lilly & Co. In 1986, Dr. Royston co-founded IDEC Corporation, discoverer of Rituxan®, the first FDA-approved monoclonal antibody to treat B-cell lymphoma, prior to its merger with Biogen.
“We are delighted to have an executive and entrepreneur of Dr.Royston’s stature join our Board,” said Bruce Cohen, Chairman. “His decades of industry leadership and keen understanding of breakthroughs in cancer therapy will be truly transformative for Viropro as we continue our efforts to build a world-class company.”
More information is available at: http://www.viropro.net/